South Korean CDMOs win major contracts across Europe, the U.S., and Japan, creating significant opportunities for API and raw material suppliers as global outsourced pharmaceutical manufacturing expands.

Genentech's giredestrant oral SERD NDA accepted by FDA under Priority Review for early-stage ER-positive breast cancer, creating new API manufacturing demand for B2B pharmaceutical suppliers.

Regeneron's expanded collaboration with CytomX adds two new targets to the $4 billion conditional bispecific antibody partnership, driving demand for specialized biologics manufacturing and Probody masking technology.

Lupin's Ranluspec becomes the first interchangeable ranibizumab biosimilar approved in the US with both vial and pre-filled syringe presentations, opening new opportunities for ophthalmic API suppliers and fill-finish manufacturers.